Illustration showing repaglinide (yellow, red and white spheres, centre-left and centre-right) binding to an ATP-dependent potassium channel (multicoloured globular structures) on a pancreatic beta cell. Repaglinide belongs to a class of drugs known as meglitinides which bind to this type of receptor on pancreatic beta cells, stimulating insulin release. Insulin, in turn, increases cellular glucose uptake, reducing blood sugar levels, making repaglinide a suitable treatment for type 2 diabetes.